Naltrexone Does Not Directly Affect Platelet Count
Naltrexone does not increase or decrease platelet count (the number of platelets in your blood). However, it can impair platelet function—specifically how platelets aggregate (clump together)—which is a different issue from platelet count.
Key Distinction: Platelet Count vs. Platelet Function
The FDA-approved labeling for naltrexone 1 does not list any effects on platelet count among its precautions, adverse effects, or laboratory monitoring requirements. The drug label explicitly states that naltrexone does not interfere with standard laboratory tests and does not mention platelet count monitoring as necessary.
Evidence on Platelet Function (Not Count)
While naltrexone doesn't change platelet numbers, there is evidence it affects platelet behavior:
Chronic naltrexone treatment (350 mg/week for 5 months) suppressed platelet aggregation induced by adrenaline and serotonin in former heroin addicts 2. This represents impaired platelet function through blockade of alpha-2 adrenoceptors and 5-HT2 receptors on platelets.
This functional impairment is mechanistically distinct from thrombocytopenia (low platelet count) or thrombocytosis (high platelet count).
Clinical Context from Guidelines
The American Heart Association guidelines 3 discuss naltrexone in the context of opioid use disorder treatment but make no mention of platelet-related concerns. Similarly, the AAP guidelines on medication-assisted treatment 4 describe naltrexone as having "very limited potential for misuse or diversion" without noting hematologic effects.
Clinical Implications
- No routine platelet count monitoring is required when prescribing naltrexone
- The suppression of platelet aggregation observed in research 2 may theoretically affect hemostasis, but this is not reflected in FDA labeling as a clinically significant concern
- If a patient on naltrexone develops bleeding concerns, investigate other causes rather than assuming naltrexone is affecting platelet count
Bottom line: Naltrexone is not associated with changes in platelet count, though it may affect platelet aggregation function at therapeutic doses.